Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest lidocaine Stories

2012-07-25 02:29:20

MISSISSAUGA, ON, July 25, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the United States Patent Office has granted the reinstatement of Patent # 6,465,709 related to Synera(®) Patch (Synera Patent).  The Synera Patent expiry date is July 7, 2020. Nuvo has listed the Synera Patent in the U.S. Food and Drug Administration's (FDA) Orange...

2012-07-11 02:25:58

PHILADELPHIA, July 11, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that it signed an amended license agreement with Ferndale Pharma Group, Inc. ("Ferndale") that grants Ferndale the right to develop, market and sell Prelude for painless,...

2012-06-07 06:25:25

WASHINGTON, June 7, 2012 /PRNewswire-USNewswire/ -- Home remedies for jellyfish stings - such as vinegar, alcohol, meat tenderizer, baking soda and urine -may be less effective at relieving pain than plain hot water and lidocaine, according to a paper published online Tuesday in Annals of Emergency Medicine ("Evidence-Based Treatment of Jellyfish Stings in North America and Hawaii") http://www.annemergmed.com/webfiles/images/journals/ymem/ntward.pdf. (Logo:...

2012-04-12 02:38:02

-- Pennsaid U.S. prescriptions increase 98% quarter-over-quarter -- New American College of Rheumatology Osteoarthritis Treatment Guidelines include recommendations for use of topical NSAIDS MISSISSAUGA, ON, April 12, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today...

2012-04-05 10:24:27

OTTAWA, April 5, 2012 /PRNewswire/ - Health Canada is informing Canadians that it has requested companies to add new risk statements to the packaging and labelling of licensed benzocaine products. In April 2011, Health Canada reminded Canadians of certain health risks associated with benzocaine products, including a very rare but serious blood condition known as methemoglobinemia that can affect sensitive individuals. The new statements are intended to further raise awareness of these...

2012-02-07 08:00:00

One patch will provide pain relief for up to 24 hours. Elmhurst, IL (PRWEB) February 07, 2012 JAR Laboratories announces the launch of their new over-the-counter pain relief patch, LidoPatch®, which contains the same active ingredient as the leading prescription patch. This new product will be ready to ship to distributors and retailers in mid-February and is poised to become a major product in the topical analgesic category. With its proven pain relieving active ingredient,...

2012-02-02 06:00:00

MISSISSAUGA, ON, Feb. 2, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced the U. S. launch of Synera® (70 mg lidocaine/ 70 mg tetracaine/ heated topical patch).  Synera is approved by the U.S. Food and Drug Administration (FDA) for use on intact skin to provide local dermal...

2012-01-04 07:54:00

BALTIMORE, Jan. 4, 2012 /PRNewswire/ -- Arcion Therapeutics, a clinical stage biotechnology company developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent for its high strength gel formulation of topical lidocaine, ARC-2022. ARC-2022 is being developed by Arcion for pain associated with post-herpetic neuralgia (PHN) and shingles. ARC-2022 has been evaluated in a single-dose Phase 1 pharmacokinetic study in adult patients...

2011-10-26 07:00:00

GREENWOOD VILLAGE, Colo., Oct 26, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced positive results of the Ampion(TM)-In-Knee (AIK) clinical trial. Michael Macaluso, Chairman of the Board, noted that, "In this first ever trial of Ampion(TM) in humans the drug was shown to be well tolerated and reduced pain over and...

2011-08-31 23:35:05

Computer-based simulations solve decades-old mystery of failed anti-arrhythmia therapy UC Davis researchers have developed an accurate computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients. The new tool -- described in the Aug. 31 issue of the journal Science Translational Medicine -- will help scientists screen anti-arrhythmia medications early in the drug-development pipeline and eventually guide physicians in...